Cardiovascular Stents Market Size to Reach US$ 23.1 Bn by 2032, Reports Persistence Market Research

The cardiovascular stents market is evolving rapidly as clinical demand, innovation, and healthcare delivery models transform the global landscape of interventional cardiology. Once considered commoditized devices, stents are now high-precision tools tailored to complex anatomies and comorbid populations. Backed by value-based care principles and minimally invasive trends, the market is experiencing notable momentum worldwide.

According to Persistence Market Research, the cardiovascular stents market is projected to grow from US$ 12.7 Bn in 2025 to US$ 23.1 Bn by 2032, registering a CAGR of 8.9%. This growth is largely driven by the increasing prevalence of cardiovascular diseases, rising procedural volumes, and clinical advancements such as drug-eluting technologies. Among product categories, coronary stents are expected to lead the segment with a 67.3% share, while North America is likely to dominate regionally, thanks to early adoption of next-generation devices and supportive reimbursement structures.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35535

Key Highlights from the Report

• Coronary stents are forecasted to contribute nearly 67.3% of global revenue in 2025.
• Drug-eluting stents (DES) continue to outpace bare-metal stents due to lower restenosis and fewer repeat procedures.
• The U.S. leads in next-gen DES adoption, aided by robust reimbursement policies and procedural demand.
• Bioresorbable and polymer-free stents are reshaping innovation pipelines and commercialization strategies.
• Lifestyle-related cardiac events are increasing emergency PCI demand, especially in urban and aging populations.
• Asia Pacific is undergoing a price-driven transformation with VBP in China and capped stent pricing in India.

Market Segmentation

The cardiovascular stents market is broadly segmented by procedure type and stent type, each serving specific clinical needs and patient groups. Coronary stenting remains the most widely performed procedure, capturing a projected 67.3% share in 2025. It is preferred due to its minimally invasive nature, faster recovery, and proven success in managing Coronary Artery Disease (CAD). As more patients are diagnosed early, the use of stents in routine PCI procedures is increasing across both developed and developing regions.

Peripheral stenting, though smaller in share, is witnessing accelerated uptake. This trend is attributed to the growing global burden of Peripheral Artery Disease (PAD)-especially in diabetic and elderly populations. Clinicians increasingly favor peripheral stents for conditions like Critical Limb Ischemia (CLI), where open surgery is riskier. Their affordability, simplicity, and shortened hospital stays are proving advantageous for both patients and healthcare systems.

From a stent type perspective, Drug Eluting Stents (DES) are set to dominate the market with nearly 65.2% share in 2025. These stents are effective in preventing neointimal hyperplasia, which reduces the need for repeat revascularization. Their ability to release antiproliferative drugs offers better outcomes in patients with complex lesions. On the other hand, bioresorbable stents are gaining traction as they eliminate the long-term risks of metallic implants and are better suited for younger patients or those requiring future reinterventions.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/cardiovascular-stents-market.asp

Regional Insights
North America Cardiovascular Stents Market Trends

North America, with a projected market share of 30.6% in 2025, continues to lead due to the high prevalence of CAD and the quick uptake of innovative stent technologies. In the U.S., initiatives that support minimally invasive procedures and same-day discharges are fueling demand for newer DES platforms. Moreover, Medicare reimbursement reforms are nudging hospitals toward advanced, clinically superior technologies.

Europe Cardiovascular Stents Market Trends

Europe's market is transitioning due to the introduction of the EU Medical Device Regulation (MDR), which has slowed product approvals and re-certifications. This has led to product shortages and delayed launches, especially of advanced DES systems. However, countries like Germany continue to invest in IVUS and OCT imaging, making it a key European hub for precision-guided PCI procedures.

Asia Pacific Cardiovascular Stents Market Trends

The Asia Pacific region is undergoing a structural shift. In China, the Volume-Based Procurement (VBP) program has drastically reduced stent prices, increasing accessibility but also intensifying price competition. In India, price caps on coronary stents continue to shape the competitive landscape, with local manufacturers gaining momentum. These policy moves are unlocking procedural growth while reshaping commercial dynamics.

Market Drivers
Growing Burden of Cardiovascular Diseases and Aging Population

The relentless rise in cardiovascular diseases, particularly in aging populations, remains the primary market driver. According to the Global Burden of Disease Study, ischemic heart disease is the world's leading cause of death, responsible for over 9 million fatalities annually. This surge is especially evident in low- and middle-income countries where rapid urbanization and sedentary lifestyles are increasing atherosclerosis cases. Consequently, interventional procedures like PCI are becoming more common, fueling stent usage.

Healthcare institutions worldwide are expanding access to cardiac catheterization labs to address this epidemic. In high-income countries, such as the U.S., a significant portion of adults over 60 have heart conditions that require stenting. Meanwhile, in emerging markets, delayed diagnoses of CAD are prompting governments to ramp up interventional cardiology programs.

Market Restraints
Procedural Risks and Allergic Reactions

Despite its effectiveness, cardiovascular stenting is not devoid of risks. Complications like bleeding, infection, and allergic reactions to stent materials or contrast agents can hinder broader adoption. Approximately 6 to 8% of PCI patients experience access-site issues such as hematomas or bleeding, which prolong hospital stays and increase mortality risks.

These complications are more frequent in elderly populations and patients with multiple comorbidities. For instance, contrast-induced nephropathy remains a serious concern in individuals with pre-existing kidney dysfunction. While these risks are managed in tertiary care settings, they still limit the widespread use of stents in high-risk populations.

Market Opportunities
Technological Advancements in Next-gen Stents

Innovations in stent design and materials are paving the way for new opportunities. Ultra-thin strut DES are showing promise in minimizing vessel trauma and promoting quicker endothelialization. This makes them ideal for small vessel diseases and complex anatomies, which were previously difficult to treat using conventional stents.

Magnesium-based bioresorbable stents are another emerging opportunity. These stents gradually dissolve after healing, thereby reducing long-term risks like late thrombosis. The MAGNITUDE trial (2024) showcased favorable results in vascular remodeling and safety. Such innovations cater to structurally healthy yet clinically vulnerable groups, thereby opening commercial prospects in niche indications.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35535

Reasons to Buy the Report

• Gain a comprehensive understanding of market dynamics, growth trends, and emerging technologies.
• Identify key segments and regions driving the cardiovascular stents market.
• Access exclusive insights from Persistence Market Research on evolving clinical and regulatory trends.
• Benchmark strategic decisions using forecasts and competitor analyses up to 2032.
• Leverage detailed segmentation and regional outlooks to guide investment or product development.

Frequently Asked Questions (FAQs)

• How Big is the Cardiovascular Stents Market?
• What is the Projected Growth Rate of the Cardiovascular Stents Market?
• Who are the Key Players in the Global Market for Cardiovascular Stents?
• What is the Market Forecast for Cardiovascular Stents in 2032?
• Which Region is Estimated to Dominate the Industry through the Forecast Period?

Company Insights

The global cardiovascular stents market is shaped by major players and emerging innovators alike. Leading companies are focusing on product diversification, regulatory compliance, and technology upgrades to maintain a competitive edge. Many are also engaging in strategic partnerships and acquisitions to enter untapped markets and accelerate innovation pipelines.

Key Players:

• Abbott Laboratories
• Medtronic plc
• Boston Scientific Corporation
• Biotronik SE & Co. KG
• Terumo Corporation
• MicroPort Scientific Corporation
• B. Braun Melsungen AG
• Cardinal Health, Inc.
• C. R. Bard, Inc.
• Cook Medical

Recent Developments:

• In January 2025, Bentley introduced the BeGraft stent graft system and BeFlared FEVAR device, targeting niche endovascular procedures.
• In May 2024, Abbott launched the XIENCE Sierra, an everolimus-eluting stent, in India after regulatory approval from CDSCO, enhancing its portfolio in emerging markets.

Conclusion

The cardiovascular stents market is undergoing a dynamic transformation marked by growing disease burden, technological innovations, and policy-driven changes in key regions. As minimally invasive procedures become the norm and patients demand better outcomes with shorter recovery times, stents are no longer mere scaffolds-they are evolving into intelligent, drug-eluting, and even dissolvable systems capable of reshaping interventional cardiology.

Looking ahead to 2032, the industry is poised for substantial growth, driven by clinical innovation, aging demographics, and global health system reforms. Strategic investments in next-gen DES, imaging integration, and biodegradable technologies will define the future of this market. With regional players rising and global companies adapting, the race for dominance in the cardiovascular stents sector is intensifying-offering exciting opportunities for stakeholders across the spectrum.

Read More Related Reports:

Ambulance Stretchers Market https://www.persistencemarketresearch.com/market-research/ambulance-stretchers-market.asp
Acute Care Hospital Beds And Stretchers Market https://www.persistencemarketresearch.com/market-research/acute-care-hospital-beds-and-stretchers-market.asp
Surgical Ronguers Market https://www.persistencemarketresearch.com/market-research/surgical-ronguers-market.asp
Medical Trolleys Market https://www.persistencemarketresearch.com/market-research/medical-trolleys-market.asp
Ozone Therapy Units Market https://www.persistencemarketresearch.com/market-research/ozone-therapy-units-market.asp
Pharmaceutical Isolators Market https://www.persistencemarketresearch.com/market-research/pharmaceutical-isolators-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.